BiotechTube

4D-150 IVT + Aflibercept IVT

Phase 2Active
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetic Macular Edema

Conditions

Diabetic Macular Edema, Diabetic Retinopathy

Trial Timeline

Aug 9, 2023 → Feb 28, 2029

NCT ID
NCT05930561

About 4D-150 IVT + Aflibercept IVT

4D-150 IVT + Aflibercept IVT is a phase 2 stage product being developed by 4D Molecular Therapeutics for Diabetic Macular Edema. The current trial status is active. This product is registered under clinical trial identifier NCT05930561. Target conditions include Diabetic Macular Edema, Diabetic Retinopathy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05930561Phase 2Active
NCT05197270Phase 1/2Recruiting

Competing Products

20 competing products in Diabetic Macular Edema

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
44
CHF6467 activeComac MedicalPhase 1/2
33
Ruboxistaurin mesylateEli LillyPhase 3
77
KVD001 InjectionKalVista PharmaceuticalsPhase 2
47
KVD001 InjectionKalVista PharmaceuticalsPhase 1
28
Baricitinib + PlaceboEli LillyPhase 2
52
LY3857210 + PlaceboEli LillyPhase 2
52
UBX1325Unity BiotechnologyPhase 2
44
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
44
UBX1325Unity BiotechnologyPhase 1
25
CT-P42 + EyleaCelltrionPhase 3
77
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
85
Anplag(Sarpogrelate) + PlaceboYuhanApproved
85
CS-3150 + placeboDaiichi SankyoPhase 2
52
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
52
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
77
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
Beraprost sodiumAstellas PharmaPre-clinical
23

Other Products from 4D Molecular Therapeutics

4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3
69
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3
69
4D-710Phase 2
44
4D-310Phase 1/2
33
4D-150 IVT + Aflibercept IVTPhase 1/2
33